Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack

JAMA - Journal of the American Medical Association

Volumn 316, Issue 1, 2016, Pages 70-78

  Wang, Yilong ^a,b   Zhao, Xingquan ^a,b   Lin, Jinxi ^a,b   Li, Hao ^a,b   Johnston, S Claiborne ^c   Lin, Yi ^d   Pan, Yuesong ^a,b   Liu, Liping ^a,b   Wang, David ^e   Wang, Chunxue ^a,b   Meng, Xia ^a,b   Xu, Jianfeng ^f,g   Wang, Yongjun ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d FUJIAN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^f FUDAN UNIVERSITY   (China)

^g NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PLACEBO; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; AGED; ALLELE; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CHINA; COMBINATION DRUG THERAPY; GENE SILENCING; GENETICS; HETEROZYGOTE; ISCHEMIC ATTACK, TRANSIENT; METABOLISM; MIDDLE AGED; SECONDARY PREVENTION; STROKE; TIME FACTOR; TREATMENT OUTCOME;

AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CHINA; CYTOCHROME P-450 CYP2C19; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENE SILENCING; GENOTYPE; HEMORRHAGE; HETEROZYGOTE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84977541065     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.8662     Document Type: Article

References (30)

1. Wang Y,Wang Y, Zhao X, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11-19.
2. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-2236.
3. Wang YJ, Zhang SM, Zhang L, et al. Chinese guidelines for the secondary prevention of ischemic stroke and transient ischemic attack 2014. Chin J Neurol. 2014;48(4):258-273. in Chinese.
4. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244-2247.
5. Mega JL, Close SL,Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
6. Bauer T, Bouman HJ, vanWerkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis. BMJ. 2011;343:d4588.
7. HolmesMV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis. JAMA. 2011;306(24):2704-2714.
8. Osnabrugge RL, Head SJ, Zijlstra F, et al. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genet Med. 2015;17 (1):3-11.
9. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.
10. Trenk D, Hochholzer W. Genetics of platelet inhibitor treatment. Br J Clin Pharmacol. 2014;77 (4):642-653.
11. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360 (4):363-375.
12. Wang YL,Wu D, Liao X, ZhangW, Zhao X, Wang YJ. Burden of stroke in China. Int J Stroke. 2007;2(3):211-213.
13. Kitzmiller JP, Groen DK, Phelps MA, SadeeW. Pharmacogenomic testing: Relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med. 2011;78(4):243-257.
14. Zhao D, Liu J, Wang W, et al. Epidemiological transition of stroke in China: 21-year observational study from the Sino-MONICA-Beijing Project. Stroke. 2008;39(6):1668-1674.
15. Wang Y, Zhao X, Jiang Y, et al. Prevalence, knowledge, and treatment of transient ischemic attacks in China. Neurology. 2015;84(23):2354-2361.
16. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94 (3):317-323.
17. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90(2):328-332.
18. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704-1714.
19. Li Z,Wang Y, Zhao X, et al. Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. J Am Heart Assoc. 2016;4(3):e003038.
20. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Stroke. 1993;24(1):35-41.
21. An international randomized trial comparing 4 thrombolytic strategies for acutemyocardial infarction. N Engl J Med. 1993;329(10):673-682.
22. Jia DM, Chen ZB, ZhangMJ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke. 2013;44(6):1717-1719.
23. McDonough CW,McClure LA,Mitchell BD, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J AmHeart Assoc. 2015;4(6):e001652.
24. SunW, Li Y, Li J, et al. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets. 2015;26(6):558-562.
25. Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ, Zou JJ. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients. Pharmazie. 2013;68(3):183-186.
26. WeiW, Fang L,Wang N, Zhang T, Zeng JB, LinMT. Prevalence of CYP2C19 polymorphisms involved in clopidogrel metabolism in Fujian Han population [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2012;29(4):420-425.
27. Hasan MS, Basri HB, Hin LP, Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci. 2013;123 (3):143-154.
28. Roberts JD,Wells GA, LeMay MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial. Lancet. 2012;379(9827):1705-1711.
29. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther. 2009;14(3):157-169.
30. Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial website. http://www.pointtrial.org. Accessed October 4, 2015.